The Multiple Myeloma Research Foundation (MMRF) recently honored Bristol-Myers Squibb Company with the 2015 Collaborator Award.
The award recognizes the company's devotion to collaboration and to accelerating the development of new multiple myeloma treatments. Among Bristol-Myers Squibb's products is Empliciti, which has been FDA-approved as a combination therapy to treat multiple myeloma patients who have previously received up to three therapies without success. The prescription medicine, used alongside Revlimid and dexamethasone, is the first and only immunostimulatory antibody approved for multiple myeloma.
"We are excited to present this award to Bristol-Myers Squibb, which acknowledges their leadership in scientific innovation and unwavering commitment to multiple myeloma," MMRF President and CEO Walter Capone said. "We appreciate their dedication to understanding and embracing the complex needs of multiple myeloma patients, to respond to health care professionals as they work to better fight this disease and to bring it all together in profound service to our community."
Multiple myeloma is a form of blood cancer that results in more than 114,000 new diagnoses each year and over 80,000 deaths.
"This award is especially meaningful to Bristol-Myers Squibb," Michael Giordano, Bristol-Myers Squibb senior vice president and head of development, said. "We are proud of the long-standing partnership with the MMRF, which has allowed us to achieve our shared goals of providing hope to those fighting this terrible cancer."
MMRF presented Bristol-Myers Squibb with the Collaborator Award during the foundation's satellite symposium at the American Society of Hematology Annual Meeting and Exposition in December.
